Rebecca N Bauer, Yanqing Xie, Suzanne Beaudin, Lesley Wiltshire, Jennifer Wattie, Caroline Muñoz, Nadia Alsaji, John Paul Oliveria, Xiaotian Ju, Jonathan MacLean, Doron D Sommer, Paul K Keith, Imran Satia, Ruth P Cusack, Paul M O'Byrne, Gizette Sperinde, Martha Hokom, Olga Li, Prajna Banerjee, Chen Chen, Tracy Staton, Roma Sehmi, Gail M Gauvreau
BACKGROUND: Similar immune responses in the nasal and bronchial mucosa implies that nasal allergen challenge (NAC) is a suitable early phase experimental model for drug development targeting allergic rhinitis (AR) and asthma. We assessed NAC reproducibility and the effects of intranasal corticosteroids (INCS) on symptoms, physiology, and inflammatory mediators. METHODS: 20 participants with mild atopic asthma and AR underwent three single blinded nasal challenges each separated by three weeks (NCT03431961)...
October 4, 2023: Clinical and Experimental Allergy